ROBINIA PSEUDOACACIA LECTIN AND ITS USES

Abstract: The present invention relates to Robinia pseudoacacia (RPA) lectin for use in medicine, to an isolated Robinia pseudoacacia lectin homopolypeptide, to compositions comprising Robinia pseudoacacia lectin, to the use of Robinia pseudoacacia lectin in the manufacture of a medicament for the reduction and/or treatment of disease, to a method for the control, reduction and/or treatment of disease and to a diet or a dietary supplement which comprises Robinia pseudoacacia lectin.

Description: ROBINIA PSEUDOACACIA LECTIN AND ITS USES The present invention relates to Robinia pseudoacacia (RPA) lectin for use in medicine, to an isolated Robinia pseudoacacia lectin homopolypeptide, to compositions comprising Robinia pseudoacacia lectin, to the use of Robinia pseudoacacia lectin in the manufacture of a medicament for the reduction and/or treatment of disease, to a method for the control, reduction and/or treatment of disease and to a diet or a dietary supplement which compπses Robinia pseudoacacia lectin Lectins are proteins or glycoprotems which are characterised by their ability to recognise specific glycoconjugate structures (Pusztai 1991) Some orallv ingested lectins are resistant to digestion in the stomach and survive intact to the intestine Within the gut, lectins may attach to carbohydrate structures expressed on the surface of \ aπous gut mucosal cells (Pusztai et al 1995) The consequence of lectin attachment to gut cells may vary For example, biological responses may depend on the administered dose At high doses, kidney bean lectin (PHA) causes a reversible disorganisation of epithelial cell vilh This is quickly repaired by endogenous processes Similarly, in the presence of large amounts of PHA in the small intestine an overgrowth of endogenous Escherichia coli occurs In addition, lipid mobilisation and glucose oxidation are increased and protein synthesis m skeletal muscle is reduced However, at low er doses of PHA. an enhanced rate of crypt cell production, resulting in hvperplastic growth m the gut. is observed (Bardocz et al 1995), but without the damaging effects whicn occur at high doses Robinia pseudoacacia (black locust) is a leguminous tree species that is common in North Ameπca and Central Europe Robinia pseudoacacia produces lectins m its bark, roots, root nodules, phloem, wood and leaves (Geitl and Ziegler 1980) and m the seeds (Van Damme et al 1995b) Although the precise function of the lectins is unknown, it is believed that the lectins may be used as a store for nitrogen in dormant peπods (Yoshida et al 1994) It is also known that the level of lectm within the bark increases duπng winter Given the known toxicity of Robinia lectins to mammals, (Nishiguchi et al 1997) it is also possible that the bark lectin may act as a defence mechanism against herbivores such as rabbits duπng winter The bark and seed lectins of Robinia pseudoacacia have been characteπsed at both the biochemical and molecular levels (Van Damme et al , 1995a, 1995b) Root lectin has also been isolated and characteπsed (Duverger et al 1997) Robinia pseudoacacia lectms (predominantly seed deπved) have had a number of uses, pπmaπly as diagnostic and research tools The specific carbohydrate binding properties (N-acetyl-D- galactosamine) of RPA have been used to investigate the carbohydrate composition of biological tissue (Raedler et al 1982) The mitogemc properties of RPA have also been used in in vitro studies to investigate the biology of isolated lymphocytes (Sabeur et al 1986, Shaπf et al 1978 & 1977) Banach et al (1983) showed that mtrapeπtoneal doses of RPA m mice induced a hepatotoxic effect including a rapid fall in liver glycogen Pusztai (1993) also showed that RPA bound strongly to the gut wall of the rat and induced pancreatic growth at high doses suggesting that RPA may damage the gut wall, promote cohform overgrowth and induce pancreatitis The lectins from the bark of Robinia pseudoacacia can be characteπsed using a range of gel separation. DNA and protein sequencing techniques (Van Damme et al 1995a) Native bark lectin eluted from a column consists of two lectins, RPbAI and RPbAII which co-puπfy at an apparent molecular weight of 120 kDa Analysis of the RPbAI on an SDS PAGE gel indicates that it is composed of two subumts, polypeptide a and polypeptide b, with molecular weights of 31 5 and 29 kDa respectively RPbAI is a tetramer composed of all the possible combinations of the a and b polypeptide monomers Polypeptides a and b have been further characteπsed by cDNA cloning and sequencing using standard techniques The predicted protein sequences of polypeptides a and b are shown m Figure 1 RPbAII is a tetramer composed of a single monomer polypeptide (subunit) c of 26 kDa molecular weight Polypeptide c has been further characteπsed and the cDNA sequenced and the predicted protein sequence is also shown in Figure 1 Robinia pseudoacacia seed contains two lectins, RPsAI and RPsAII which co-puπfy at an apparent molecular weight of 120 kDa (Van Damme et al, 1995b) Analysis of both lectins on SDS PAGE indicates that they are each compπsed of a single monomer subunit (34 and 29 kDa respectively) The seed lectins have been characteπsed by cDNA cloning and sequencing techniques and the predicted protein sequence is shown in Figure 2 Recently published work on the root lectins has shown that they are composed of two lectins (Duverger et al, 1997) The root lectins appear to differ from those of seed and bark in that they are dimer molecules classified as RPrAI and RPrAII of molecular weights 58 and 63 kDa respectively RPrAI is a heterodimer consisting of a 31 and a 29 kDa subunit and RPrAII is a homodimer consisting of single 30 kDa subunits Studies on Robinia pseudoacacia lectins have generated some confusion concerning the precise molecular weight, and subunit composition of the individual lectins Wantyghem et al (1986) identified two lectins m seeds, RPA 1 a dimer and RPA 3 a tetramer However, m the same year Fleischmann et al (1986) descπbed the isolation ot two tetramer lectins termed RPA 1 and RPA 2 with similar subunit molecular weights It appears therefore that the lectins may exist as monomer, dimer, tπmer and tetramer forms Mucosal cells make up mucous membranes which are the moist membrane lining many tubular structures and cavities of living bodies They include the mucous coveπng of the gut, the mouth, the nasal passage, the oesophagus, the stomach, the lung, the small intestine, and the large intestine (including the rectum) The importance of mucous membranes in the viability of an organism has long been recognised However, the ability to control mucosal and non-mucosal cell proliferation has never previously been recognised as an opportunity to address many physiological problems, including diseased and damaged cells and/or tissues A number of disorders of mucosal cells are known, including conditions where cell division is accelerated, decelerated, where the mucosal cells aie damaged or where the protective outer layer such as mucous is missing Conditions related to the abnormal control of mucosal cell proliferation may include skin cancers, psoπasis, lmtable bowel syndrome, inflammatory disease and mucositis Mucositis is a painful and debilitating condition in which the rapidly growing epithelial and mucosal cells are damaged and the external mucous layer is removed and/or not replaced sufficiently quickly Mucositis may result in infection by microorganisms which are present, for example, in the mouth or gut In this text, mucositis covers all gut lesions (which may occur as an after-effect of damage to the mucous membrane) The condition is seen as a major side effect m the treatment of cancer The incidence and seventy of mucositis may increase with increasing rounds of cancer therapy, and may ultimately affect treatment compliance and survival The solution which the present invention provides exploits the tissue protecting qualities and the metabolic effects of lectins on biological mateπal Diseased and damaged cells, which cannot repair or regenerate sufficiently quickly can cause seπous and potentially life-threat ening health πsks Also a problem in maintaining normal cell functions are metabolic diseases such as obesity, hyperglycemia, cardiovascular disease, stroke and gastrointestinal disease, including irπtable bowel svndrome. inflammatory bowel disease and coehac disease Cells and tissues can become diseased and damaged through a wide vaπety of causes Cell damaging agents include chemotherapeutic agent(s), radiotherapy, chemιcal(s) (organic or inorganic), toxιn(s), acid, alkali, a radiation source, a free radical, and may cause damage, by surgery or therapy in an attempt to treat an alternative, more problematic disease The treatment of cancer is a pπme example of damage caused to cells and/or tissues of an organism as a side-effect of other procedures The treatment of cancer is based pπmaπly upon the use of chemotherapy or radiotherapy, either alone, together or in combination with surgery Chemotherapy uses a cytotoxic agent to directly damage the DNA of a target cell If a sufficient dose ot the cytotoxic agent is administered to a target tissue 1 e a tumour, DNA mis-repair may result m the accumulation of DNA mutations, lesions and chromosomal aberrations that ultimately result in cell death Radiotherapy uses radiation to either damage the DNA of a target cell directly, or exploits the potential of ionising radiation to produce free radicals which are able to break DNA strands (Steel, 1996). The use of chemotherapy or radiotherapy is therefore a compromise m trying to induce most damage to the cancerous cells by targeting the radiation without irreparably destroying normal tissue Although chemotherapy and radiotherapy are the most widely used treatments for cancer, the rates of survival are limited due to a number of factors The key factor is that the cytotoxic drug or radiation does not discπmmate between normal and cancerous tissue In most cases, it is impossible to give a sufficient dose of cytotoxic drug or radiation to reliably kill all cancerous tissue as it would prove fatal to the patient Common side effects for existing therapy regimes include hair loss, bone marrow suppression, nausea, vomiting and diaπhoea (Paulsen et al 1996) In addition there are also many instances where the use of radiotherapy, particularly to the pelvic regions has resulted in altered gastrointestinal function (Yeoh et al 1993) and long term damage to the gut which requires surgery (van Halteren et al 1993) A major breakthrough has been made in the last 10 years with the availability of hematopoietic growth factors It is now possible to give higher doses of cytotoxic drugs and then rescue tissues such as bone marrow and white blood cells by the administration of recombinant growth factors such as granulocyte-macrophage colony-stimulating factor (Erkisis et al. 1996) Such an approach has enabled improved prognosis and survival rates to be achieved Whilst epidermal-specific growth factors such as epidermal growth factor are known, the complex nature of gut growth regulation has made it difficult to develop effective gut "rescue" procedures (Podolsky, 1993) As no such growth factor currently exists for the gut, damage to the gastrointestinal tract by cytotoxic drugs and radiation has now become dose limiting The present invention overcomes problems m the art by providing a new and effective product and the use thereof which enables positive and controlled growth in and of biological mateπal Accordingly, a first aspect of the invention provides Robinia pseudoacacia lectin for use m medicine The use m medicine is widespread It includes the control of mucosal cell proliferation, the reduction and/or treatment of damage caused by a cell- damaging agent, the reduction and/or treatment of a metabolic disorder, or a combination of two or more thereof Throughout this text, "reduction" means any effect which mitigates any damage or any medical disorder, to any extent, and includes prevention (prophylactic use) Throughout this text, "treatment" means any amelioration of disorder, disease, syndrome, condition, pam or a combination of two or more thereof Treatment by the present invention (or use of compositions) may be earned out duπng an additional "treatment", such as chemotherapy and/or radiotherapy Robinia pseudoacacia lectm is particularly useful in the control of mucosal cell proliferation as it relates to the reduction and/or treatment of mucositis, including gut lesions Control of mucosal cell proliferation is particularly useful in the reduction and/or treatment of damage caused by a cell-damagmg agent Typical cell damaging agents of all aspects of the present invention include radiotherapy, chemotherapy or a combination thereof In the present application the terms "radiation" and "radiotherapy" are used as having the same meaning, which is a source of radiation (irradiation) which may, or may not be applied as a therapeutic technique The invention is of particular applicability to the reduction and/or treatment of damage to mammalian tissue, more particularly human tissue The present invention is of particular importance to human tissue because of the considerable requirement for radiotherapy and/or chemotherapy in the treatment of cancer However, the present invention is also applicable to other animals and biological matter, m particular to the veteπnary industry, including farm animals and pets Robinia pseudoacacia for use in medicine relates to all cells and/or tissues, and includes cells and tissues within a whole body as well as outside of a whole body, including isolated cells and tissues It relates to all biological matter, including whole bodies and parts thereof The invention also relates to matter which is subjected, intentionally or unintentionally, to any cell-damagmg agent The invention is of particular use to biological matter which is particularly sensitive to cell-damagmg agents such as radiotherapy and/or chemotherapeutic agents Such biological matter includes mucous membranes, in particular the mucosal coveπngs of the gut, the mouth, the nasal passage, the oesophagus, the stomach, the lung, the small intestine, the large intestine (including the colon and the rectum), epithelial tissue (eg covenng the eye) as well as any other mucosal cell and/or tissue and non-mucosal cells and tissues such as bone marrow, spleen, all blood generating cells, blood tissue, thymus, hair-producmg tissue, eye tissue, reproductive tract, testicular/prostate tissue or two or more thereof The present invention is particularly relevant to mucous membranes which are tissues lining hollow structures in the body and include the permanently moist tissues lining the eyes The sensitivity of cells and tissues to damage by a cell-damagmg agents may be linked to its metabolic status It is the growth factor effect of Robinia pseudoacacia lectin, m particular on the gut (and especially the small intestine) which is understood to be important in the prophylactic and/or therapeutic affects pπor to, duπng and/or following administration of cell- damaging agents Robinia pseudoacacia lectin is particularly effective in the control of mucosal cell proliferation pπor to, duπng and/or following radiotherapy, chemotherapy or a combination thereof The invention is achieved as a result of the protectiv e and repair capabilities of Robinia pseudoacacia lectin Mucosal cells are those which make up any mucous membrane (the moist membrane lining many tubular structures and cavities) Many are those which provide a protective layer between the external environment and the internal organs of an animal Mucosal cells/tissues include mucosal coveπngs of the gut, the mouth, the nasal passage, the oesophagus, the stomach, the lung, the small intestine, the large intestine, epithelial tissue, reproductive tract and others The first aspect of the invention relates to all of these Other cells and tissues to which the first aspect of the invention relates include, bone marrow, spleen, blood generating cells, blood tissue, thymus, hair-producing tissue, eye tissue, the reproductive tract, testicular/prostate tissue and combinations of two or more thereof In accordance with the present invention, the use of Robinia psuedoacacia lectin in medicine may be in combination with a cytoprotectant The cytoprotectant is preferably a radiosensitiser, a chemoprotectant (including free-range scavangers), a growth factor or a combination of two or more thereof From the above list of cytoprotectants the following examples are preferred radiosensitisers- vitamin K mimetics such as Synkavit or Menadione, gadolinium texaphynn or lobenguane (([[3-ιodo- 13311)phenyl]methyl]guamdme) chemoprotectants- Sulcraphate, cysteme, cysteamme, Ethyol, balazipone or dosmalfate, free radical scavengers - WR 3689 (2-[[3- methylammo)propyl]ammo]ethanedιol dihydrogen phosphate ester, AD 20 (2-[[2- methoxyphenyl)acetyl]ammo]-2-propenoιc acid or nitroxide antioxidant, growth factors- granulocyte colony-stimulatmg factor (G-CSF), granulocyte-macrophage colony- stimulatmg factor (GM-CSF), Erythropoietm (EPO), epidermal growth factor (EGF), keratmocyte growth factor (KGF), transforming growth factor (TGF α and β), any interleukin including IL-11 and IL-15, insulin-like growth factor (IGF), nerve growth factor (NGF), platelet deπved growth factor (PDGR), Bombesin, Relaxin, Calcitonin. colostrum-denved growth factor (CDGF), amlexanox or amoxanox, protegπn, pilocarpine hydrochloπde, stem cell factor (STF), thrombopoietm, steel factor (SF), any interferon, including interferon or any cytokme In addition to cytoprotectants, the use of the lectin may be in combination with one or more other compounds/agents (preferably pharmaceutical) In particular, anti-microbial agents may be included Such agents may be included to fight secondary infections, for example secondary infections associated with mucositis The Robinia pseudoacacia lectin for use in medicine is particularly useful in relation to cells of the gastrointestinal tract (for both reduction and repair of damage and in relation to metabolic disease) The control may be for an increase in functional and/or length of the gastrointestinal tract or for control of the nature and/or density of gastrointestinal-cell expressed surface glycoprotems Other uses in relation to control of mucosal cell proliferation include the reduction and/or treatment of bowel disorders such as inflammatory bowel disease and lrntable bowel syndrome as well as the reduction and/or treatment of gut lesions, and the repair and replacement of mucosal cells pπor to, duπng or following, radiotherapy, chemotherapy or a combination of two or more thereof The applications of these control features includes (a) Gut cell proliferation leadmg to an increase in functional gut area and length which could be a useful therapy where gut function is impaired as for instance via surgery or accident, and/or (b) Control of gut cell turnover rates which may allow control over the nature and density of expressed surface glycoconjugates as these become progressively more complex as cells age As the glycoconjugates affect certain gut properties. such as propensity to bacteπal attachment, lectin administration could be envisaged as a therapeutic or prophylactic control for these properties In particular, the control of cell proliferation may be used for obtaining an increased nutπent capacity of the small intestine and/or controlling cell gut expression of glycoconjugates Such effects are not necessaπly medical disorders and mav be only cosmetic or functional, above and beyond the satisfactory medical level These effects may also be useful for the Robinia pseudoacacia lectm use in reduction and/or treatment of a metabolic disorder Metabolic disorders include any disorder which is related to and/or a result of the metabolism of the body, in particular obesity and obesity related disorders such as hyperglycaemia (type II diabetes), cardiovascular, stroke, gastrointestinal and gastromtestmal-related conditions A metabolic disorder may require the control of mucosal cell proliferation, or the control of mucosal cell proliferation may be independent of a metabolic disorder Also covered is the non-medical reduction of weight which may be purely cosmetic In accordance with the invention, the higher the lectin concentration, the faster may be the reduction and/or treatment of any medical disease or other non-medical symptoms However, vaπous factors may influence the preferred concentration of lectin dosage, as discussed herein In the present invention the Robinia pseudoacacia lectin may be those in either naturally occurπng compositions or puπfied therefrom, chemically synthesised or produced by recombmant technology The lectin may be modified or a deπvative (naturally occurπng or synthetic) Methods are well known in the art for the production of lectins, both puπfication from natural sources and by recombmant technology (Pusztai and Palmer, 1977, Carvalho, 1993 and US Patent no 4.889,842) The lectins according to the invention are preferably functional equiv alents to "oπgmally" isolated Robinia pseudoacacia lectins The functionality of any Robinia pseudoacacia lectin can be determined m accordance with its ability to attach to specific glycoconjugate structures Most preferably, a polypeptide is a Robinia pseudoacacia lectin according to the present invention if it is an equivalent (or lectin vaπant as defined herein after), l e , 40%, preferably 50%, preferably 60%, more preferably 70%, even more preferably, 80% or more identical at the ammo acid level or DNA sequence level to any known Robinia pseudoacacia lectin, for example the lectins set out in Figure 1 or 2 A "lectin vaπant" as refeπed to herein, means a polypeptide substantially homologous to native lectin, but which has an ammo acid sequence different from that of native lectin (human, muπne or other mammalian species) because of one or more deletions, insertions or substitutions The vaπant amino acid sequence preferably is at least 80% identical to a native lectin ammo acid sequence, most preferably at least 90% > identical The percent identity may be determined, for example, by compaπng sequence information using the GAP computer program, version 6 0 described by Devereux et al (Nucl Acids Res 12 387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG) The GAP program utilises the alignment method of Needleman and Wunsch (J Mol Biol 48 443, 1970). as revised by Smith and Waterman (Adv Appl Math 2 482, 1981) Since lectins are proteins, they are clearly subject to destabihsation/denaturation by a number of parameters such as heat, acid, alkali etc Since the use of lectins in the present invention (throughout) requires their protein properties it is important that the lectins are not completely destroyed or denatured pπor to or dunng their use (eg in the strong acid conditions of the stomach and the mild alkali conditions of the lower gut) Accordingly, the Robinia pseudoacacia lectins for use in the present invention may need to be first characteπsed with regard to how they mav be affected duπng processing and/or administration Such charactensation is standard technology and can be conducted easily by any person skilled in the art The concentration of lectin required for any of the aspects of the invention will vary if the lectin has been denatured or destabilised in any way The concentrations of Robinia pseudoacacia lectins which have been provided in this text are based on their natural properties with effectively no reduction of their activity by denaturation or destabihsation Thus, the concentrations of lectins which are provided are not absolute but reflect the activity of the lectm Accordingly, a composition, for example, which has a lectin whose activity has been reduced by half, but which is present in double the concentration is the same as a composition which has half the quantity of lectin but where the activity of the lectin has not been altered Furthermore, the activity of any lectin may be increased by modification, for example duπng recombmant production and/or by producing truncated mutants which have increased activity The same considerations as to the concentration verses activity of lectin also applies to lectins with increased activity All modified Robinia pseudoacacia lectins or deπvatives thereof are covered by the present invention, including those with increased or decreased activities, and include, for example, truncated lectin subumts and/or differently glycosylated versions with full or modified activity Also included are protein sequences which include one or more of the cπtical ammo acids involved in biological activity of any lectin (preferably all of those ammo acids and all of the biological activity) For example, the active regιon(s) of RPA polypeptide b sequence are descπbed in Nishiguchi et al, 1997, and include the following, (ammo acid position), aspartate 87, phenylalanine 130, threonine 215, leucme 217, seπne 218 The Robinia pseudoacacia lectin according to the first aspect of the invention may be from, or is an equivalent to a lectin from any part of the Robinia pseudoacacia plant, preferably bark, seed, root, root nodule, phloem or wood or a combination of two or more thereof In accordance with the present invention, the Robinia pseudoacacia lectin may compπse only one polypeptide subunit The polypeptide subunit may be any of those known m the art (e g RPbAI (a or b), RPbAII(c), RPsAI or RPsAII. RprAI or RPrAII) or an equivalent thereto, or is a polypeptide subunit not yet identified Preferably, the Robinia pseudoacacia lectin of the first aspect of the invention compπses a monomer, a dimer, a tπmer or a tetramer of subumts, or a combination of two or more thereof This enables mimicking of polypeptide groupings as they occur in nature The monomer, dimer, tπmer, tetramer may be of the same, or more than one type of polymer subunit The tetramer preferably compπses four bark polypeptide a subumts, four bark polypeptide b subumts or an intermediate mixture of a and b subumts The lectin polypeptides may compπse or coπespond to one or more of the ammo acid sequences as set out in Figure 1 or Figure 2, preferably at least 40, 50, 60, 70, 80, 90, 100% homologous thereto (as a lectin vaπant as descπbed above) A second aspect of the invention provides an isolated Robinia pseudoacacia lectin which is a homotetramer, a homotπmer, a homodimer or a single subunit, preferably puπfied to a level of 60% or more In this text, the term "puπfied" means substantially without impunties Robinia pseudoacacia lectin at these levels of purity is preferred for use in pharmaceutical compositions and use in medicine The Robinia pseudoacacia lectin is preferably puπfied to a level of 70, 80, 90%, or above, most preferably 95%, 99% or 100% Preferred features of the first aspect of the invention, as described above, also apply to the second aspect of the invention A third aspect of the invention provides a composition compπsing a Robinia pseudoacacia lectin preferably either puπfied to a level of 60% (preferably 70, 80, 90, 95 or 100%o) or a RPA lectin according to the second aspect of the invention in combination with a pharmaceutically acceptable excipient Preferably the composition is a pharmaceutical composition which compπses a pharmaceutically acceptable excipient Suitable excipients include pharmaceutical grade starch, gelatin. oil. sugar, alcohol or water (preferably steπle) The composition may be a mixed preparation for administration, or may be a combined preparation for simultaneous, separate or sequential use (or administration) In a combined preparation, the lectin and any other components may be separate and may be administered in any order Features and preferred features of the first and second aspects of the invention, as descπbed above, also apply to the third In particular, the composition may compπse a Robinia pseudoacacia lectin in combination with a cytoprotectant as hereinbefore descnbed A fourth aspect of the invention provides a method for producing a composition according to the third aspect of the invention compnsmg admixing the lectin with a pharmaceutically acceptable excipient Preferred features of the fourth aspect are as descnbed for the first to third aspects A fifth aspect of the invention provides the use of Robinia pseudoacacia lectin in the manufacture of a medicament for the control of mucosal cell proliferation, for the reduction and/or treatment of damage caused by a cell-damagmg agent, for the reduction and/or treatment of a metabolic disorder or a combination thereof Features and preferred features of the first to fourth aspects of the invention also apply to the fifth. A sixth aspect of the invention provides a method for the control of mucosal cell proliferation, for the reduction and/or treatment of damage caused by a cell-damagmg agent, for the reduction and/or treatment of a metabolic disorder or a combination thereof in a patient m need thereof, compnsmg admimsteπng to an individual an effective amount of Robinia pseudoacacia lectin Features and preferred features of the first to fifth aspects of the invention also apply to the sixth The patient is deemed to be in need of the method, in particular where they will undergo, are undergoing or have undergone radio and or chemotherapy and, in particular, if they are suffeπng from cancer. A seventh aspect of the invention provides a diet or a dietary supplement compnsmg Robinia pseudoacacia lectin The diet and/or dietary supplement can be for use according to the first aspect of the mv ention The diet and/or dietary supplement may contnbute towards non-medically related weight loss The diet and/or dietary supplement applies to any animal, including humans The diet or dietary supplement according to the seventh aspect of the invention is preferably for a peπod from 2 to 5 days, or for an indefinite (long-term) duration Features of the first to sixth aspects of the invention, as descπbed above, also apply to the seventh The diet or dietary supplement preferably compnses a total lectin content of up to 0 3g, preferably 0 2g per kg body weight per day At least some of the lectin should be from Robinia pseudoacacia (preferably from 1 to 100% of the lectin content of the diet or dietary supplement) The Robinia pseudoacacia lectm may be any one, or a combination of two or more, as descnbed above, according to the first aspect of the invention Such a diet and/or dietary supplement is useful in medicine, in particular in the control of mucosal cell proliferation, for the reduction and/or treatment of damaged caused by a cell-damagmg agent, for the reduction and/or treatment of a metabolic disorder, or a combination of two or more thereof The diet and/or dietary supplement according to the seventh aspect of the invention is particularly useful when followed by a penod duπng which a high quality diet is administered A higher quality diet, according to the present invention, can be defined as a diet which provides all of the essential protein, fats, carbohydrates, minerals and vitamins necessary for the normal growth of an animal The essential components of the higher quality diet are preferably in an optimal ratio A high quality diet should not contain any component which would slow or inhibit the growth and development of the animal A prefeπed features of a high quality diet is that there is a positive conversion of food eaten into lean body weight The high quality diet preferably follows on immediately, or shortly after (up to 2 days), the lectin diet, and/or dietary supplement according to the seventh aspect of the invention The high quality diet is most useful for a peπod of up to 7 days, advantageously for a peπod of up to 5 days The diet and/or dietary supplement may also be advantageous for use m the long term (greater than one month, preferably greater than one year) treatment of metabolic disorders and cosmetic weight loss When using m combination with a cell-damaging agent (although not necessaπly at the same time of administration), the lectin feeding part of the diet is best restncted to a penod of up to 5 days, because 48 - 72 hours may be insufficient to complete a full cycle of intestinal turn over and to thereby obtain the benefits of higher nutπent absorption and utilisation rates m the control feeding part of the diet The high quality feeding part of the cycle is best restncted to about 5 days, in order to obtain maximum improvements m feed conversion efficiency Preferably, the diet and/or dietary supplement which compnses a penod of feeding with Robinia pseudoacacia lectin, followed by a peπod of feeding with a higher quality diet, is repeated at least twice to form a cyclic diet The cycles may be repeated up to 20 times, preferably up to 10 times, most preferably up to 6 times The cyclic diet descπbed provides transient increases in nutπent uptake efficiency which are mediated by Robinia pseudoacacia lectin administration Therefore, by cycling of lectin containing and lectin free diets, enhancement of nutntionally dependent situations can be engineered For example, with appropπate dietary timing, an athlete can optimise performances for major events The diet and/or dietary supplement to the seventh aspect of the invention is particularly useful pπor to or after, a method of treatment by irradiation and/or chemotherapy In such situations, the diets may be even more effective when used in combination with a cytoprotectant, such as those descnbed for the first aspect of the invention Features and preferred features of the first to sixth aspects also apply to the seventh A eighth aspect of the invention provides a method to produce each of the second, fourth and seventh aspect of the invention as descnbed above Production of the punfied lectin according to the second aspect involves either the isolation and punfication of Robinia pseudoacacia lectin from Robinia pseudoacacia (eg from a plant or tissue culture) or to the synthetic production (eg by recombmant technology) Production of a composition according to the fourth aspect involves combining the lectin with any one or more ingredients for the composition Production of the diet and/or dietary supplement involves obtaining Robinia pseudoacacia lectin and optionally combining with any one or more ingredients for a diet and/or dietary supplement Preferred features of aspects one to seven of the invention also apply to the eighth For each of the aspects of the invention which may be involved in medicine or involve any administration to biological tissue, the particular dosage regime will ultimately be determined by the attending physician and will take into consideration such factors as the lectin or lectins being used, animal type, age, weight, seventy of symptoms and/or seventy of treatment being or to be applied, method of administration, adverse reactions and/or other contraindications Specific defined dosage ranges can be determined by standard designed clinical tnals with patient progress and recovery being fully monitored Such tnals may use an escalating dose design using a low percentage of the maximum tolerated dose m animals as the starting dose in man Preliminary guidance for dosage ranges can be taken from the results given in the expeπmental section of this text and by the following ranges which have been extrapolated to humans An appropriate upper limit appears to be a concentration of a lectin up to approximately 0 3 g per kg body weight per day A concentration of 0 3 g per kg body weight per day may well produce an upset gastro-mtestinal tract in a patient but these symptoms may be acceptable on the basis that the patient has an increase chance of survival from diseases such as cancer An appropriate lower limit appear to be a concentration of lectm around 0 0001 mg (0 1 μg) per kg body weight per day Preferred intermediate dosage concentrations include the presence of a lectin up to approximately 0 2 g, 0 15 g and 0 05 g per kg body weight per day, and thereafter of concentrations approximately 1 mg, 0 5 mg, 0 1 mg, 0 01 mg and 0 005 mg per kg body weight per day The medicaments for all aspects of the present invention can be used to provide the required concentration of lectin in one or more "intake" per day ("intake" including any form of administration and also descπbing a dosage unit) Some aspects of the invention may suit a single intake of a high lectin concentration, whereas others may suit a number of intakes, evenly or unevenly spaced over the same penod, but with a lower lectin concentration per intake Use of the lectin m any medicament (including the manufacture of medicaments) according to the present invention may be in combination with a suitable pharmaceutical earner and/or excipient Such earners and excipients are well known in the art (eg Handbook of Pharmaceutical Excipients (1994) 2 nd Edition, Eds A Wade/P J Weller The Pharmaceutical Press, Amencan Pharmaceutical Association) Of particular use according to the present invention are compositions and/or medicaments which are formulated in a colonic drug dehvery system, a mouthwash, a cream, a paste or in a capsule The medicament manufactured according to any aspect of the invention is preferably admimstered bv mouth (orally), nasally (for example via a nasal spray) or rectally (for ease of route to one or more parts of the alimentary canal) although parenteral or intravenous administration of the medicament may also be used The present invention will now be illustrated by the following examples EXAMPLES Preparation of lectm from the bark of Robinia pseudoacacia The Robinia bark lectins may be prepared essentially as descπbed by Van Damme et al., (1995 a) from partially punfied bark extracts on immobilised fetuin Bark tissue was homogenised m 20mM acetic acid containing 200 mg/1 ascorbic acid (10 ml/g fresh weight) using a blender The homogenate was squeezed through cheesecloth, adjusted to pH 5 0 (with 1M NaOH), and centnfuged for 10,000g for 10 minutes. The resulting supernatant was filtered through glass wool to remove floating particles. After adding 1.5 g/1 CaCl 2 , the extract was brought to pH 9.0 (with 1M NaOH) and kept overnight at 4°C. The resulting precipitate was removed by centrifugation and the cleared extract adjusted to pH 3.8 with lm HC1. After standing overnight again at 4°C, the extract was cleared by centrifugation and adjusted to pH 7.0 with 1M NaOH and brought to 1M ammonium sulphate by adding the solid salt. The solution was then degassed and recentrifuged. The cleared supernatant was loaded onto a fetuin agarose column equilibrated with 1M ammonium sulphate (pH 7.0). After passing the extract, the column was washed with ammonium sulphate until the A? 8 o fell below 0.01. The lectin was. then desorbed with 20mM diaminopropane (pH 1 1). The desorbed lectin was adjusted to pH 7.0 with 1M HC1 and bought to 1M ammonium sulphate by adding the solid salt. After centrifuging at 15.000g for 20 minutes, the supernatant was loaded on a column of phenyl-Sepharose equilibrated with 1M ammonium sulphate. Impurities were removed by washing with 1M ammonium sulphate and the lectin desorbed using a linear gradient of 1M ammonium sulphate to water. Fractions were collected and the A 28 o determined to identify those containing lectin. It is known that the bark lectin is produced by Robinia pseudoacacia in response to shortening day length i.e. the onset of winter. By using bark material in winter, yields of lectin in the region of 10 mg/g may be attained. Preparation of AΛ and B 4 RPA bark lectin isotypes The A 4 and B 4 homotetramer isotypes may be prepared using a step gradient ion exchange chromatography method. A 100 ml Hyper-D S column (BioSepra) was equilibrated with five column volumes of 50 mM sodium acetate pH 4.75. Freeze dried RPA lectin (obtained as described in the above preparation) was dissolved in acetate buffer (50mM sodium acetate, pH 4.75) and centrifuged for 10 minutes at 20,000g. The clarified supernatant was applied to the column and the column subsequently washed with acetate buffer at a flow rate of 3 ml/min. A step gradient was constructed using 50 mM sodium acetate pH 4.75 + NaCl . The XaCl was added in increasing concentrations in 5, 7, 9, 12 and 100%o step gradients. The fractions containing lectin were selected by measuring the absorbance at 280 nM. The A4 tetramer was eluted in the 5.7% salt fraction and the B tetramer in the 9-12% salt fraction. The fractions containing pure A or B were confirmed using conventional PAGE and SDS-PAGE methods. Characterisation of lectins from the bark of Robinia pseudoacacia The lectins from the bark of Robinia pseudoacacia can be characterised further using ion exchange chromatography, gel filtration and in vitro cell agglutination assays. Such methods are well known in the art and are described in Van Damme et al 1995a and b. Animal management Thirty five young male Hooded Lister (Rowett Strain) rats (19 days old weighing 30- 40g) were housed individually in grid bottom cages. The animals were fed a high quality semi-synthetic diet containing 10% lactalbumin protein (Table 1). Table 1 Composition of diet. (g/kg diet) Maize starch 373 Potato starch 100 Glucose 150 Corn oil 150 Vitamin mix 50 Mineral mix 50 Lactalbumin 127 Silicic acid 0.4 For composition of vitamin and mineral mixes see Carvalho (1992). Diet and water was freely available at all times except on day 19 when the amount of food offered was restricted to lOg/rat. At 19 days, rat weights were 100-104g. Administration of RPA Animals pre-dosed with RPA were given the equivalent of 25, 50 or 100 mg/kg body weight RPA (Table 2) in 0.9% saline by gavage. The animals were pre-dosed for three consecutive days prior to the 5-FU injection. Administration of saline Animals not pre-dosed with RPA were administered with 1 ml 0.9% saline by gavage. Administration of 5-FU 300mg of 5-fluorouracil was stirred in 14ml of distilled water. 1M NaOH was added slowly until the 5-FU had dissolved. The solution was made up to a final volume of 20 ml. The final pH of the solution was 8.3. A dose of 150 mg/kg body weight was administered to the animal by intraperitoneal injection. Immediately after the injection, the rats were offered 15g of the control diet. The ability of orally ingested lectins from Robinia pseudoacacia to protect rats from a high dose of chemotherapy, and in particular its tissue protectant effect on the gut. Five groups, each consisting of 5 rats were fed on the standard diet containing lactalbumin (Table 1). One group of rats were fed 8 g per day of standard diet for three days and then injected with 5-FU at 150 mg/kg body weight (Table 2). Table 2. Dietary protocol Treatment Dietary protocol 1 LA 3d, inject 5-FU, LA 6d 2 25 mg/kg RPA 3d, inject 5-FU, LA 6d 3 50 mg/kg RP A 3 d, inject 5-FU, LA 6d 4 100 mg/kg RPA 3d, inject 5-FU, LA 6d 5 100 mg/kg RPA 3d, LA 6 d Key LA = lactalbumin RPA = Robinia pseudoacacia lectin 5-FU = 5-Fluorouracil The rats were pair fed for the first three days and then fed ab libitum post 5-FU injection. Three groups of animals were gavaged daily with 25, 50 or 100 mg/kg/day body weight Robinia pseudoacacia lectin (RPA) for three days and then injected with 150 mg/kg 5-FU on the following day. The remaining group of animals were pre-dosed with 100 mg/kg body weight RPA and then returned to lactalbumin containing diet without injection of 5-FU. After injection with 5-FU, the animals were returned to lactalbumin containing diet ad lib. The animals were sacrificed 7 days after the start of the experiment, the carcass dissected and the small intestine, jejunum and ileum wet weights recorded. The results are shown in Table 3. Table 3. The effect of pre-dosing with Robinia pseudoacacia lectin for 3 days on the small intestine, jejunum and ileum wet weights (g). Treatment Dosing regime Small Jejunum Ileum intestine (g) (g) (g) 1 LA + 5-FU 5.62 1.0 1.0 2 25 mg/kg RPA + 5-FU 5.41 1.03 0.98 50 mg/kg RPA + 5-FU 5.74 1.12 1.08 4 100 mg/kg RPA + 5-FU 6.33 1.27 1.12 5 100 mg/kg RPA 6.99 1.27 1.17 The results show a dose-dependent increase in wet weight for all tissues examined with increasing dose of RPA. Thus, pre-dosing with RPA was able to protect tissues of the small intestine, jejunum and ileum from damage induced by 5-FU. Pre-dosing with 100 mg kg RPA (treatment 4) gave the best tissue protectant effect when compared to the animals fed lactalbumin alone (treatment 1). Animals pre-dosed with 100 mg/kg RPA and injected with 5-FU (treatment 4) had similar small intestine, jejunum and ileum wet weights to animals fed 100 mg/kg RPA alone (treatment 5). Visual inspection of the small intestine, jejunum and ileum indicated that animals treated with 5-FU alone (treatment 1) had no, or a very thin mucosal layer on the gut tissue. Animals treated with 5-FU and RPA however had healthy looking gut tissue with a normal mucosal layer. This example demonstrates that oral administration of Robinia pseudoacacia lectin (RPA) before injection with 5-FU gave a significant tissue protective effect on the small intestine, jejunum and ileum. The ability of orally ingested homotetramer AJ and BΔ. lectins from Robinia pseudoacacia to protect rats from a high dose of chemotherapy, and in particular its tissue protectant effect on the gut. Five groups, each consisting of 5 rats were fed on a standard diet containing lactalbumin (Table 1) and were fed on the following dietary regime (Table 4); Table 4. Dietary protocol Treatment Dietary protocol 1 LA 7d 2 LA 3d, inject 5-FU, LA 4d 3 200 mg/kg homotetramer 3d, inject 5-FU, LA 4d 4 200 mg/kg B 4 homotetramer 3d, inject 5-FU, LA 4d One group of animals (Treatment 1) were fed standard diet throughout. The second group were gavaged daily with saline for three days and then injected with 5-FU at 150 mg/kg body weight (Treatment 2). The remaining two groups (Treatment 3 & 4) of animals were gavaged daily for three days with either A 4 or B 4 RPA homotetramer for three days and then injected with 150 mg/kg body weight 5-FU. After injection with 5-FU, Treatment groups 2-4 were returned to standard diet for four days ad lib. The animals were sacrificed 7 days after the start of the experiment, the carcass dissected and the small intestine, jejunum and ileum dry weights recorded. The results are shown in Table 5. Table 5. The effect of pre-dosing with Robinia pseudoacacia AΛ. or BJ homotetramer lectin for 3 days on the small intestine, jejunum and ileum drv weights (mg). Treatment Dosing regime Small Jejunum Ileum Intestine (mg) (mg) (mg) 1 LA 2531 519 415 2 LA + 5-FU 1789 336 405 200 mg/kg A 4 2597 632 421 4 200 mg/kg B 4 2093 439 419 Dry weights normalised to lOOg dry body weight. The results show that treatment with 5-FU had a large effect on the small intestine and in particular the jejunum. Animals treated with 5-FU had a significant reduction in tissue dry weight versus the untreated control (Treatments 1 & 2). Pre-treatment with either the A 4 or B homotetramer lectin however gave a significant tissue protectant effect (Treatment 3 & 4). In particular, animals treated with the t homotetramer lectin had tissue dry weights essentially the same as that of the untreated animals. Visual inspection of the small intestine, jejunum and ileum indicated that the animals treated with 5-FU alone had extensively damaged mucosal on the gut tissue. However, the animals treated with the A or B 4 homotetramer lectin had essentially a normal looking mucosal layer. This example demonstrates that both the A and B 4 homotetramer Robinia pseudoacacia lectin were able to give significant protective effect on the gut when administered before injection with 5-FU. References Banach M , Zaremba S , Sadouska M (1983) Disturbances of liver and muscle glycogen level as well as blood glucose level in mice following administration of lectin extracted from Robinia pseudoacacia Folia Biol (Krakow) Vol 31, pp 177- 186 Bardocz, S , Grant, G , Ewen, S W B , Duguid, T J , Brown, D S , Englyst. K & Pusztai, A (1995) Reversible effect of Phytohaemagglutmm on the growth ana metabolism of the rat gastrointestinal tract Gut, 37, 353-360 Carvalho, A F F U de, (1992) Dietary kidney bean lectins affect insulin levels change gene expression and modulate metabolism PhD thesis, University of Aberdeen Denekamp, J ( 1996) The broad spectrum of preclmical radiobiology British contnbutions International Journal of Radiation Oncology, Biology & Physics, 36 497-509 Duverger, E and Delmotte, F M Punfication of lectins from Robinia pseudoacacia L root-tips Plant Science 123 9-18, (1997) Erkisi, M , Erkurt, E , Ozbarlas, S , Burgut, R , Doran, F & Seyrek, E ( 1996) The use of recombmant human granulocyte colony-stimulating factor in combination with single or fractionated doses of isofamide and doxorubicin in patients with soft tissue sarcoma Journal of chemotherapy, 8, 224-228 Fleischmann, G and Rudiger, H (1986) Isolation, resolution and partial charactensation of two Robinia pseudoacacia seed lectins Biol Chem Hoppe- Seyler, 367, 27-32 Gietl, C and Ziegler H , Biochem, Physiol Planzen 175, 58-66 (1080) Lehnmger, A L , Nelson, D L & Cox, M C (1997) Pπnciples of biochemistry. Worth Publishers, New York Nishiguchi, M., Yoshida, K., Sumizono, T. & Tazaki, T. ( 1997). Studies by site directed mutagenesis of the carbohydrate binding properties of a bark lectin from Robinia pseudoacacia. FEBS Letters, 403, 294-298. Paulsen, F., Hoffmann, W., Kortmann, R.D., Porschen, R. & Bamberg, M. (1996). Akute gastrointestinal Nebenwirkungen in der Radio-onkologie - Was ist gesichert in der Therapie?. Strahlenther. Onkol. 172, 53-56 (Nr 2). Podolsky, D.K. (1993). Regulation of intestinal epithelial proliferation: a few answers, many questions. Pusztai. A. (1991). Plant Lectins. Cambridge: Cambridge University Press. Pusztai, A. (1993) Dietary lectins are metabolic signals for the gut and modulate immune and hormone functions. Eur J of Clin Nut, 47, 691-699. Pusztai, A., Ewan, S.W.B., Grant G., Peumans, W.J., Van Damme, E.J.M., Coates, M.E. and Bardocz, S. (1995). Lectins and also bacteria modify the glycosylation of gut receptors in the rat. Glycoconjugate Journal, 12, 22-35. Raedler, A., Boehle A., Otto, U. & Raedler, E. (1982). Differences of glycoconjugate exposed on hypernephroma and normal kidney cells. Journal of Urology, 128, 1109- 1113. Sabeur. G., Wantyghem, J & Schuller, E. (1986). Stimulation of 2',3'-cyclic nucleotide 3'-phosphodiesterase in human lymphocytes by Robinia pseudoacacia lectin. Biochemie, 68, 581-585. Sharif, A., Brochier, J. & Bourrillon, R. (1977). Specific activation of Human T lyphocytes by Robinia pseudoacacia seeds lectin. Cellular Immunology, 31, 302-310. Sharif, A., Lethibichthuy, J., Brochier, J., Goussalt, Y. & Bourrillon, R. (1978). Activation of human B lymphocytes induced by Robinia pseudoacacia lectin in the presence of T cells. Immunology, 35, 643-649. Steel, G.G. (1996). From targets to genes: a brief history of radiosensitivity. Phys Med. Biol., 41 , 205-222. Van Damme, E.J.M., Barre, A., Smeets, K., Torrekens, S., Van Leuven, F., Rouge, P. & Peumans, W.J. (1995a). The bark of Robinia pseudoacacia contains a complex mixture of lectins. Plant Physiol., 107, 833-843. Van Damme, E.J.M., Barre, A., Rouge, P., Van Leuven, F., and Peumaas, W. (1995b). The seed lectins of black locust (Robinia pseudoacacia) are encoded by two genes which differ from the bark lectin genes. Plant Molecular Biology, 29, 1 197- 1210. Van Halteren, H.K., Gortzak, E., Taal, B.G., Helmerhorst, Th, J, M., Aleman, B.M.P., Hart, A. A.M. & Zoetmulder, F.A.N. (1993). Surgical intervention for complications caused by late radiation damage of the small bowel: a retrospective analysis. European Journal of Surgical Oncology, 19, 336-341. Wantyghem, J., Goulut, C, Frenoy, J.P., Turpin, E. and Goussault, Y. (1986). Purification and characterisation of Robinia pseudoacacia seed lectins. A re- investigation. Biochem J., 237, 483-489. Yeoh, E., Horowitz, M., Russo, A., Muecke, T., Ahmad, A. & Chatterton, B. (1993). International Journal of Radiation Oncology, Biology & Physics, 26, 229-237. Yoshida, K., Baba, K., Yamamoto, N. & Tazaki, K (1994). Cloning of a lectin cDNA and seasonal changes in levels of the lectin and its mRNA in the inner bark of Robinia pseudoacacia. Plant Mol. Biol. (1994), 25, 845-853.

Claims: CLAIMS 1 Robinia pseudoacacia lectin for use in medicine. 2 Robinia pseudoacacia lectin as claimed in claim 1, wherein the use is for the control of mucosal cell proliferation, for the reduction and/or treatment of damage caused by a cell-damaging agent, for the reduction and/or treatment of a metabolic disorder, or a combination of two or more thereof 3 Robinia pseudoacacia lectin as claimed in claim 2. wherein the use is for the control or reduction and/or treatment of mucositis 4 Robinia pseudoacacia lectin as claimed in any one of claims 1 to 3, for mammalian cells and or tissues, in particular human cells and/or tissues 5. Robinia pseudoacacia lectin as claimed in claim 4, wherein the cell and/or tissue is a mucous cell, including a mucous membrane 6 Robinia pseudoacacia lectin as claimed in any one of claims 1 to 5, which compnses bark, seed, root, root nodule, phloem, wood or leaf lectin, or a combination of two or more thereof 7 Robinia pseudoacacia lectin as claimed in any one of claims 1 to 6, which compπses at least one polypeptide subunit from any Robinia pseudoacacia lectin 8. Robinia pseudoacacia lectin as claimed in any one of claims 1 to 7, which compπses a dimer, tπmer or tetramer of lectin subumts, or a combination of two or more thereof 9. Robinia pseudoacacia lectin as claimed in claim 8, comprising a tetramer of four bark polypeptide a subunits or four bark polypeptide b subunits or a mixture of bark a and b subunits. 10. Robinia pseudoacacia lectin, comprising a homotetramer, a homotrimer, a homodimer or a single subunit, purified to a level of 60%> or above. 1 1. Robinia pseudoacacia lectin as claimed in claim 10, which comprise bark subunits a or b. 12. A composition comprising Robinia pseudoacacia lectin preferably either: purified to a level of 60% or more, or as claimed in claim 10 or claim 1 1. 13. A composition as claimed in claim 12, wherein the composition comprises a pharmaceutically acceptable excipient. 14. A composition, as claimed in claim 12 or claim 13, for use in medicine. 15. A method for producing a composition, as claimed in claim 13 or claim 14, comprising admixing the lectin and the pharmaceutically acceptable excipient. 16. Use of Robinia pseudoacacia lectin in the manufacture of a medicament for the control of mucosal cell proliferation, for the reduction and/or treatment of damage caused by a cell-damaging agent, for the reduction and/or treatment of a metabolic disorder or a combination thereof. 17. Use of Robinia pseudoacacia lectin, as claimed in claim 16, wherein the use is for the control or reduction and/or treatment of mucositis. 18. Use, as claimed in claim 16 or claim 17, wherein the Robinia pseudoacacia lectin comprises bark, seed, root, root nodule, phloem, wood, leaf or a combination of two or more thereof. 19. Use, as claimed in any one of claims 16 to 18, wherein the lectin comprises a dimer, trimer or tetramer of subunits or a combination of two or more thereof. 20. Use, as claimed in claim 20, wherein the lectin comprises a homopolypeptide. 21. Use, as claimed in any one of claims 16 to 21, wherein the lectin is a homotetramer of bark subunits a or b. 22. Use, as claimed in any one of claims 16 to 21, wherein the lectin is as claimed in any one of claims 10 to 11, or a composition as claimed in any one of claims 12 to 14. 23. A method for the control of mucosal cell proliferation, for the reduction and/or treatment of damage caused by a cell-damaging agent, for the reduction and/or treatment of a metabolic disorder or a combination thereof in a patient in need thereof, comprising administering to an individual an effective amount of Robinia pseudoacacia lectin. 24. A method, as claimed in claim 23, wherein the patient is suffering from or is likely to suffer from mucositis. 25. A method, as claimed in claim 24 or claim 25, wherein the patient is undergoing or due to undergo treatment by a cell-damaging agent. 26. A method, as claimed in claim 25, wherein the patient is suffering from cancer. 27. A method, as claimed in any one of claims 23 to 26, wherein the Robinia pseudoacacia lectin is as claimed in any one of claims 1 to 14. 28. A diet or dietary supplement comprising Robinia pseudoacacia lectin.

Inventors: BARDOCZ ZSUSZANNA MAGDOLNA, FISH NEIL WILLIAM, PALMER RICHARD MICHAEL JOHN, PUSZTAI ARPAD JANOS, BARDOCZ, ZSUSZANNA, MAGDOLNA, FISH, NEIL, WILLIAM, PALMER, RICHARD, MICHAEL, JOHN, PUSZTAI, ARPAD, JANOS
Applicants: ALIZYME THERAPEUTICS LTD, BARDOCZ ZSUSZANNA MAGDOLNA, FISH NEIL WILLIAM, PALMER RICHARD MICHAEL JOHN, PUSZTAI ARPAD JANOS, ALIZYME THERAPEUTICS LIMITED, BARDOCZ, ZSUSZANNA, MAGDOLNA, FISH, NEIL, WILLIAM, PALMER, RICHARD, MICHAEL, JOHN, PUSZTAI, ARPAD, JANOS
Application year: 1998
Main classification: A61K35
IPC codes: A61K36, A61K38, A61K125, A61K127, A61K129, A61K131, A61P1, A61P35, A61P39, C07K14